TrialCancer chemotherapy and pharmacology2015

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.

Andrew Gabrielson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.